atrasentan has been researched along with 8-epi-prostaglandin f2alpha in 2 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (8-epi-prostaglandin f2alpha) | Trials (8-epi-prostaglandin f2alpha) | Recent Studies (post-2010) (8-epi-prostaglandin f2alpha) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 1,863 | 248 | 723 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dabbs Loomis, E; Elmarakby, AA; Pollock, DM; Pollock, JS | 1 |
| Chen, CC; Hsu, YJ; Lee, TM | 1 |
2 other study(ies) available for atrasentan and 8-epi-prostaglandin f2alpha
| Article | Year |
|---|---|
ETA receptor blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor-deficient rats.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Aorta; Atrasentan; Blood Pressure; Dinoprost; Disease Models, Animal; Down-Regulation; Endothelin A Receptor Antagonists; Endothelins; Hypertension; Male; Pyrrolidines; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Sodium Chloride, Dietary; Superoxides; Time Factors | 2004 |
Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia.
Topics: Allopurinol; Analysis of Variance; Animals; Antioxidants; Atrasentan; Biomarkers; Cyclic N-Oxides; Dinoprost; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Fibrosis; Gout Suppressants; Hypertrophy, Left Ventricular; Hyperuricemia; Isoprostanes; Male; Myocardial Infarction; Myocardium; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; RNA, Messenger; Spin Labels; Superoxides; Time Factors; Up-Regulation; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling; Xanthine Oxidase | 2011 |